Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 159

1.

Expression of organic anion-transporting polypeptide 1A2 and organic cation transporter 6 as a predictor of pathologic response to neoadjuvant chemotherapy in triple negative breast cancer.

Hashimoto Y, Tatsumi S, Takeda R, Naka A, Ogane N, Kameda Y, Kawachi K, Shimizu S, Sakai M, Kamoshida S.

Breast Cancer Res Treat. 2014 May;145(1):101-11. doi: 10.1007/s10549-014-2913-y. Epub 2014 Mar 27.

PMID:
24671357
2.

Common and discriminative clinicopathological features between breast cancers with pathological complete response or progressive disease in response to neoadjuvant chemotherapy.

Osako T, Horii R, Matsuura M, Ogiya A, Domoto K, Miyagi Y, Takahashi S, Ito Y, Iwase T, Akiyama F.

J Cancer Res Clin Oncol. 2010 Feb;136(2):233-41. doi: 10.1007/s00432-009-0654-9. Epub 2009 Aug 14.

PMID:
19685074
3.
4.

Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.

Kim MJ, Kim EK, Park S, Moon HJ, Kim SI, Park BW.

Acta Radiol. 2015 Sep;56(9):1069-77. doi: 10.1177/0284185114548507. Epub 2014 Sep 16.

PMID:
25228161
5.

Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer.

Takeda R, Naka A, Ogane N, Kameda Y, Kawachi K, Shimizu S, Kamoshida S.

Breast Cancer (Auckl). 2015 Aug 4;9:49-57. doi: 10.4137/BCBCR.S27534. eCollection 2015.

6.

The role of immunohistochemistry in breast cancer patients treated with neoadjuvant chemotherapy: an old tool with an enduring prognostic value.

Sánchez-Muñoz A, Plata-Fernández YM, Fernández M, Jaén-Morago A, Fernández-Navarro M, de la Torre-Cabrera C, Ramirez-Tortosa C, Lomas-Garrido M, Llácer C, Navarro-Perez V, Alba-Conejo E, Sánchez-Rovira P.

Clin Breast Cancer. 2013 Apr;13(2):146-52. doi: 10.1016/j.clbc.2012.11.006. Epub 2013 Jan 11.

PMID:
23318089
7.

Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.

Petit T, Wilt M, Velten M, Rodier JF, Fricker JP, Dufour P, Ghnassia JP.

Breast Cancer Res Treat. 2010 Nov;124(2):387-91. doi: 10.1007/s10549-010-1142-2. Epub 2010 Sep 8.

PMID:
20824324
8.

[Immunohistochemical phenotype of breast carcinomas predicts the effectiveness of primary systemic therapy].

Kulka J, Tokés AM, Tóth AI, Szász AM, Farkas A, Borka K, Járay B, Székely E, Istók R, Lotz G, Madaras L, Korompay A, Harsányi L, László Z, Rusz Z, Molnár BA, Molnár IA, Kenessey I, Szentmártoni G, Székely B, Dank M.

Magy Onkol. 2009 Dec;53(4):335-43. doi: 10.1556/MOnkol.53.2009.4.2. Hungarian.

9.
10.

Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer.

Tanioka M, Sakai K, Sudo T, Sakuma T, Kajimoto K, Hirokaga K, Takao S, Negoro S, Minami H, Nakagawa K, Nishio K.

Breast Cancer Res Treat. 2014 Oct;147(3):513-25. doi: 10.1007/s10549-014-3121-5. Epub 2014 Sep 9.

PMID:
25200445
11.

Cytoplasmic poly(adenosine diphosphate-ribose) polymerase expression is predictive and prognostic in patients with breast cancer treated with neoadjuvant chemotherapy.

von Minckwitz G, Müller BM, Loibl S, Budczies J, Hanusch C, Darb-Esfahani S, Hilfrich J, Weiss E, Huober J, Blohmer JU, du Bois A, Zahm DM, Khandan F, Hoffmann G, Gerber B, Eidtmann H, Fend F, Dietel M, Mehta K, Denkert C.

J Clin Oncol. 2011 Jun 1;29(16):2150-7. doi: 10.1200/JCO.2010.31.9079. Epub 2011 Apr 25.

PMID:
21519019
12.

ER, PgR, HER-2, Ki-67, topoisomerase IIα, and nm23-H1 proteins expression as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.

Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, Ma B, Song X.

Med Oncol. 2011 Dec;28 Suppl 1:S48-54. doi: 10.1007/s12032-010-9693-y. Epub 2010 Sep 25.

PMID:
20872186
13.

Evaluation of ER, PgR, HER-2, Ki-67, cyclin D1, and nm23-H1 as predictors of pathological complete response to neoadjuvant chemotherapy for locally advanced breast cancer.

Li XR, Liu M, Zhang YJ, Wang JD, Zheng YQ, Li J, Ma B, Song X.

Med Oncol. 2011 Dec;28 Suppl 1:S31-8. doi: 10.1007/s12032-010-9676-z. Epub 2010 Sep 16.

PMID:
20844986
14.

Benefit from anthracyclines in relation to biological profiles in early breast cancer.

Rocca A, Bravaccini S, Scarpi E, Mangia A, Petroni S, Puccetti M, Medri L, Serra L, Ricci M, Cerasoli S, Biglia N, Maltoni R, Giunchi DC, Gianni L, Tienghi A, Brandi M, Faedi M, Sismondi P, Paradiso A, Silvestrini R, Amadori D.

Breast Cancer Res Treat. 2014 Apr;144(2):307-18. doi: 10.1007/s10549-013-2819-0. Epub 2014 Jan 1. Erratum in: Breast Cancer Res Treat. 2014 Apr;144(2):319. Faedi, Monica [corrected to Faedi, Marina].

PMID:
24381054
15.

PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer.

Loibl S, von Minckwitz G, Schneeweiss A, Paepke S, Lehmann A, Rezai M, Zahm DM, Sinn P, Khandan F, Eidtmann H, Dohnal K, Heinrichs C, Huober J, Pfitzner B, Fasching PA, Andre F, Lindner JL, Sotiriou C, Dykgers A, Guo S, Gade S, Nekljudova V, Loi S, Untch M, Denkert C.

J Clin Oncol. 2014 Oct 10;32(29):3212-20. doi: 10.1200/JCO.2014.55.7876. Epub 2014 Sep 8.

PMID:
25199759
16.

BRCAness predicts resistance to taxane-containing regimens in triple negative breast cancer during neoadjuvant chemotherapy.

Akashi-Tanaka S, Watanabe C, Takamaru T, Kuwayama T, Ikeda M, Ohyama H, Mori M, Yoshida R, Hashimoto R, Terumasa S, Enokido K, Hirota Y, Okuyama H, Nakamura S.

Clin Breast Cancer. 2015 Feb;15(1):80-5. doi: 10.1016/j.clbc.2014.08.003. Epub 2014 Sep 28.

17.

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.

Pentheroudakis G, Kalogeras KT, Wirtz RM, Grimani I, Zografos G, Gogas H, Stropp U, Pectasides D, Skarlos D, Hennig G, Samantas E, Bafaloukos D, Papakostas P, Kalofonos HP, Pavlidis N, Fountzilas G.

Breast Cancer Res Treat. 2009 Jul;116(1):131-43. doi: 10.1007/s10549-008-0144-9. Epub 2008 Jul 31.

PMID:
18668363
18.

Influence of neoadjuvant chemotherapy on HER2/neu status in invasive breast cancer.

Li P, Liu T, Wang Y, Shao S, Zhang W, Lv Y, Yi J, Wang Z.

Clin Breast Cancer. 2013 Feb;13(1):53-60. doi: 10.1016/j.clbc.2012.09.011. Epub 2012 Oct 26.

PMID:
23103368
19.

Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancer.

Matsubara N, Mukai H, Fujii S, Wada N.

Breast Cancer Res Treat. 2013 Jan;137(1):203-12. doi: 10.1007/s10549-012-2344-6. Epub 2012 Nov 27.

PMID:
23184081
20.

FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.

Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.

Breast. 2013 Oct;22(5):691-7. doi: 10.1016/j.breast.2012.12.020. Epub 2013 Feb 12.

PMID:
23414930

Supplemental Content

Support Center